newsFDA approves first biosimilar to Neulasta5 June 2018 | By European Pharmaceutical ReviewThe U.S. Food and Drug Administration has approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment.
newsOgivri approved as the first biosimilar against certain breast and stomach cancers4 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene...
